tafenoquine has been researched along with trimetrexate in 1 studies
| Studies (tafenoquine) | Trials (tafenoquine) | Recent Studies (post-2010) (tafenoquine) | Studies (trimetrexate) | Trials (trimetrexate) | Recent Studies (post-2010) (trimetrexate) |
|---|---|---|---|---|---|
| 186 | 37 | 113 | 422 | 50 | 21 |
| Protein | Taxonomy | tafenoquine (IC50) | trimetrexate (IC50) |
|---|---|---|---|
| Dihydrofolate reductase | Mycobacterium avium | 0.3012 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0207 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.1435 | |
| Dihydrofolate reductase | Saccharomyces cerevisiae S288C | 0.042 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1798 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.026 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0378 | |
| Dihydrofolate reductase | Candida albicans | 0.04 | |
| Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.008 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.5788 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.0202 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0794 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Queener, SF | 1 |
1 review(s) available for tafenoquine and trimetrexate
| Article | Year |
|---|---|
New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.
Topics: Animals; Drug Design; Humans; Immunosuppression Therapy; Molecular Structure; Opportunistic Infections; Pneumonia, Pneumocystis; Structure-Activity Relationship | 1995 |